Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Streptococcus pneumoniae type 9N capsular polysaccharide is a serotype-specific carbohydrate polymer forming the capsule of S. pneumoniae. It is a major virulence factor, protecting the bacterium from host immune responses. The repeating unit is a linear pentasaccharide: →4)-α-D-GlcpA-(1→3)-α-D-Glcp-(1→3)-β-D-ManpNAc-(1→4)-α-D-Glcp-(1→4)-β-D-GlcpNAc(1→. Type-specific immunity relies on recognition of unique epitopes on the capsule, making it a target for vaccines against pneumococcal disease.
Vaccines elicit type-specific antibodies that opsonize bacteria expressing the 9N capsule, promoting phagocytosis and clearance. Antibodies can also neutralize the capsule's antiphagocytic properties.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Streptococcus pneumoniae type 9N capsular polysaccharide (CPS 9N).